These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25637603)

  • 1. Delineation of a conserved arrestin-biased signaling repertoire in vivo.
    Maudsley S; Martin B; Gesty-Palmer D; Cheung H; Johnson C; Patel S; Becker KG; Wood WH; Zhang Y; Lehrmann E; Luttrell LM
    Mol Pharmacol; 2015 Apr; 87(4):706-17. PubMed ID: 25637603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Informatic deconvolution of biased GPCR signaling mechanisms from in vivo pharmacological experimentation.
    Maudsley S; Martin B; Janssens J; Etienne H; Jushaj A; van Gastel J; Willemsen A; Chen H; Gesty-Palmer D; Luttrell LM
    Methods; 2016 Jan; 92():51-63. PubMed ID: 25986936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo.
    Gesty-Palmer D; Yuan L; Martin B; Wood WH; Lee MH; Janech MG; Tsoi LC; Zheng WJ; Luttrell LM; Maudsley S
    Mol Endocrinol; 2013 Feb; 27(2):296-314. PubMed ID: 23315939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-Arrestin-biased signaling of PTH analogs of the type 1 parathyroid hormone receptor.
    van der Lee MM; Verkaar F; Wat JW; van Offenbeek J; Timmerman M; Voorneveld L; van Lith LH; Zaman GJ
    Cell Signal; 2013 Feb; 25(2):527-38. PubMed ID: 23159578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biased agonism at the parathyroid hormone receptor: a demonstration of functional selectivity in bone metabolism.
    Bohinc BN; Gesty-Palmer D
    Mini Rev Med Chem; 2012 Aug; 12(9):856-65. PubMed ID: 22681253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translating in vitro ligand bias into in vivo efficacy.
    Luttrell LM; Maudsley S; Gesty-Palmer D
    Cell Signal; 2018 Jan; 41():46-55. PubMed ID: 28495495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biasing the parathyroid hormone receptor: relating in vitro ligand efficacy to in vivo biological activity.
    Appleton KM; Lee MH; Alele C; Alele C; Luttrell DK; Peterson YK; Morinelli TA; Luttrell LM
    Methods Enzymol; 2013; 522():229-62. PubMed ID: 23374189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-arrestin-biased agonism at the parathyroid hormone receptor uncouples bone formation from bone resorption.
    Bohinc BN; Gesty-Palmer D
    Endocr Metab Immune Disord Drug Targets; 2011 Jun; 11(2):112-9. PubMed ID: 21476967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation.
    Gesty-Palmer D; Flannery P; Yuan L; Corsino L; Spurney R; Lefkowitz RJ; Luttrell LM
    Sci Transl Med; 2009 Oct; 1(1):1ra1. PubMed ID: 20368153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arrestins in bone.
    Bohinc BN; Gesty-Palmer D
    Prog Mol Biol Transl Sci; 2013; 118():335-58. PubMed ID: 23764060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid hormone (PTH) and PTH-related peptide domains contributing to activation of different PTH receptor-mediated signaling pathways.
    Cupp ME; Nayak SK; Adem AS; Thomsen WJ
    J Pharmacol Exp Ther; 2013 Jun; 345(3):404-18. PubMed ID: 23516330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-arrestin-dependent parathyroid hormone-stimulated extracellular signal-regulated kinase activation and parathyroid hormone type 1 receptor internalization.
    Sneddon WB; Friedman PA
    Endocrinology; 2007 Aug; 148(8):4073-9. PubMed ID: 17525124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergent biological properties of arrestin pathway-selective biased agonism.
    Appleton KM; Luttrell LM
    J Recept Signal Transduct Res; 2013 Jun; 33(3):153-61. PubMed ID: 23448506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis.
    Polyzos SA; Makras P; Efstathiadou Z; Anastasilakis AD
    Expert Opin Investig Drugs; 2015 Feb; 24(2):145-57. PubMed ID: 25316089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass?
    Gesty-Palmer D; Luttrell LM
    Br J Pharmacol; 2011 Sep; 164(1):59-67. PubMed ID: 21506957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-arrestin-biased parathyroid hormone ligands: a new approach to the development of agents that stimulate bone formation.
    Ferrari SL; Bouxsein ML
    Sci Transl Med; 2009 Oct; 1(1):1ps1. PubMed ID: 20368152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulated expression of G protein-coupled receptor kinases (GRK's) and beta-arrestins in osteoblasts.
    Spurney RF
    Calcif Tissue Int; 2003 Aug; 73(2):153-60. PubMed ID: 14565597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arrestin pathways as drug targets.
    Luttrell LM
    Prog Mol Biol Transl Sci; 2013; 118():469-97. PubMed ID: 23764065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. β-Arrestin-biased signaling mediates memory reconsolidation.
    Liu X; Ma L; Li HH; Huang B; Li YX; Tao YZ; Ma L
    Proc Natl Acad Sci U S A; 2015 Apr; 112(14):4483-8. PubMed ID: 25831532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fulfilling the Promise of "Biased" G Protein-Coupled Receptor Agonism.
    Luttrell LM; Maudsley S; Bohn LM
    Mol Pharmacol; 2015 Sep; 88(3):579-88. PubMed ID: 26134495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.